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ABSTRACT

The present invention is directed to D-alanine racemase
mutants of mycobacterial species. The D-alanine racemase
gene (alrA) is involved in the systhesis of D-alanine, a basic
component of peptidoglycan that forms the backbone of the
bacterial cell wall. The present invention is also directed to
methods of making live-attenuated vaccines against pathogenic mycobacteria using such alrA mutants and to the
vaccines made according to such methods. The present
invention is further directed to use of alrA mutants in
methods for screening antimycobacterial agents that are
synergistic with peptidoglycan inhibitors. Finally, the
present invention is directed to methods to identify new
pathways of D-alanine biosynthesis for use in developing
new drugs targeting peptidoglycan biosynthesis in mycobacteria and to identify vaccines useful against pathogenic
mycobacteria.
10 Claims, No Drawings
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D-ALANINE RACEMASE MUTANTS OF
MYCOBACTERIA AND USES THEREFORE
CROSS-REFERENCE TO RELATED
APPLICATIONS
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The present application claims priority from provisional
patent application Ser. No. 601341,485, filed Dee. 18,2001,
which is incorporated herein by reference.

lo
STATEMENT REGARDING GOVERNMENT
RIGHTS
This
was made with government
United States Department of Agriculture, USDA Cooperative State Research Service Project Grant No. NEB. 14-108. 1s
The Government may have certain rights in this invention.
BACKGROUND OF THE INVENTION

like masses caused by chronic inflammatory processes) or
"tubercules" that are seen in advanced cases. Due to the
significance of mycobacterial diseases, prevention and control measures, including vaccines, diagnostics and therapies
are of major importance.
Microorganisms of the M. avium complex have achieved
prominence as major opportunistic pathogens of AIDS
patients. M. avium is naturally resistant to most firstline
antituberculosis drugs (Inderlied et al., 1993). This threat to
public health has been partially met by therapy with appropriate antimicrobial agents, but unfortunately drug-resistant
M. avium and M. tubevculosis strains readily. appear
(Chaisson et al., 1994; Espinal et al., 2000), underscoring the
need to develop new and more effective anti-mycobacterial
agents,
Mycobactevium smegmatis is a fast-growing nonpathogenic mycobacterial species particularly useful in studying
basic cellular processes of relevance to pathogenic mycobacteria. The D-alanine racemase gene (alrA) is involved in
the synthesis of D-alanine, abasic componenf of peptidoglycan that forms the backbone of the cell wall. Biosynthesis of
the mycobacterial cell wall has received considerable attention in the search for inhibitors useful for drug therapy
(Chatterjee, 1997). These cell walls display a complex
architecture of glycolipids and proteins linked to the
mycolyl-arabinogalactan-peptidoglycanbackbone (McNeil
and Brennan, 1991). This structure is a barrier that contributes to drug resistance (Trias and Benz, 1994), and many of
its components have been found to play a major role in
pathogenesis (Daffe and Draper, 1998). The analysis of the
M. tubevculosis genome sequence suggests that peptidoglycan biosynthesis in mycobacteria follows the general pathway of other bacteria, including the formation of the basic
building block D-alanyl-D-alanine (Belanger and Inamine,
2000; Cole et al., 1998). D-alanine racemase (Alr) catalyzes
the conversion of L-alanine into D-alanine (Julius et al.,
1970), and D-alanine-D-alanine ligase catalyzes the subsequent dimerization of D-alanine into the key d i ~ e ~ t i d e
D-alan~l-D-alanine(Neuhaus, 1962). The corresponding
enzymes from both Eschevichia coli (Lambert and Neuhaus,
f 972; Neuhaus and Lynch, 1964) and m~cobacteria (C
aceres, 1999; David et al., 1969) are inhibited by
D-cycloserine (DCS), a D-alanine analog (Neuhaus, 1967).
The d i ~ e ~ t i is
d ethen added to the UDP-tri~e~tide
Precursor
byl the action
adding enzyme that
~ of ~the D-alanine-D-alanine
~
completes the reactions of the D-alanine branch of peptidOgl~can
(Walsh, 1989).
DCS is particularly effective against mycobacteria albeit
with marked side effects (Cummings et al., 1955; Yew et al.,
1993). Moreover, overproduction of Air in MYcobactevium
smegmatis, MYcobactevium intvacellulave, and MYcobactevium bovis BCG leads to a DCS-resistant phenotype. The&
.'
smegmatis enzyme is inhibited by DCS in a ~~ncentrationdependent manner ( ~ a c e r e set al., 1997). Likewise, the M.
avium and M. tubevculosis enzymes produced from E. coli
recombinant clones are also inhibited by DOS (Strych et al.,
2001). Nonetheless, the specific characteristics of the mycobacterial enzymes involved in peptidoglycan biosynthesis,
including the essentiality of each of their functions, remain
unknown. Such knowledge would be important to the design
of specific inhibitors that would serve as novel bactericidal
agents to treat M. tubevculosis and M. avium infections.
Furthermore, the inactivation of the genes encoding for
these enzymes may lead to the generation of attenuated
strains of pathogenic mycobacteria that could serve as
candidate vaccines against tubevculosis.
M. smegmatis has been extensively used as a model
system for M. tubevculosis and other mycobacteria. M.
\

The present invention is directed to D-alanine racemase
mutants of mycobacterial species, The D-alanine racemase

20

gene (alrA) is involved in the synthesis of D-alanine, a basic
component of peptidoglycan that forms the backbone of the
bacterial cell wall. The present invention is also directed to
methods of making
vaccines against patho- 25
genic
using such alrA mutants and
the
vaccines made
such
The Present
invention is further directed to use of alrA mutants in
methods for screening antim~cobacterialagents that are
synergistic with peptidoglycan inhibitors. Finally, the 30
present invention is directed to methods to identify new
pathways of D-alanine biosynthesis for use in developing
new drugs targeting peptidoglycan biosynthesis in mycobacteria and to identify vaccines useful against pathogenic
mycobacteria.
3s
The publications and other materials used herein to illuminate the background of the invention or provide additional
details respecting the practice, are incorporated by reference,
and for convenience are referenced in the following text by
author and date and are listed alphabetically by author in the 40
appended bibliography.
Mycobacteria cause a number of diseases in humans and
animals including tubevculosis, which is the leading cause of
human death from an infectious disease in the world (
~
& Murray, 1992). M. tubevculosis is the principal cause of 45
tubevculosis in humans and other primates and is occasionally seen in dogs, pigs and cattle (O'Reilly & Daborn, 1995).
In contrast, M, bovis, the etiologic agent of bovine
tubevculosis, has a wide host range and infects ruminants,
carnivores, and primates, including humans (Pritchard, so
1988). For M. bovis and M. tubevculosis in both humans and
animals, contaminated aerosols are the most common routes
of transmission (Carleton, 1993). Other mycobacterial
pathogens of importance are M. avium, M. pavatubevculosis,
and M. lepvae. M. avium is the agent of tubevculosis in birds ss
but its major significance is as an opportunistic pathogen of
AIDS patients (Inderlied et al., 1993). M. pavatubevculosis
is the etiologic agent of Johne's disease, a granulomatous
enteritis in ruminants and it has also been linked to a
potential etiology of a type of inflammatory bowel disease 60
(Crohn's disease) in humans (Cocito et al., 1994; Harris and
Barletta, 2001). Finally, M. lepvae infects humans and
armadillos. Though leprosy in humans has low mortality, its
morbidity is quite high in affected areas, estimated to have
been 1&12 million in the 1980s (Noordeen, 1991). All these 6s
diseases caused by mycobacteria are characterized pathologically by the formation of granulomatous nodules (tumor-
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smegmatis is nonpathogenic, requiring less stringent conThe present invention employs the following definitions.
tainment facilities, and it grows at a relatively high rate in a
"alrA" and "alr" refer to the D-alanine racemase gene,
variety of defined and nutrient-restricted media (Jacobs,
including normal alleles of the alrA gene.
2000). M. smegmatis has been used to study drug resistance
"AlrA" and "Alr" refer to D-alanine racemase enzyme.
mechanisms (ciceres et al.9 1997; Peteroy et al.9 2000;
i'Displays increased susceptibility to antimycobacterial
Telenti et al.9 1997) and basic ~ h ~ s i o l o g i c aprocesses
l
refers to a reduction in the minimal inhibitory conthe
peptidog1ycan precursors (Ciril10
centration of the mutant strain when
with the wild
et al., 1998; Pavelka and Jacobs, 1996). Insights gained from
type strain,
these studies can then be applied to the pathogenic myco"Displays increased susceptibility to bactericidal action of
lo
bacteria.
phagocytic
- . cells" refers to a reduction in the ability of the
mutant strain to survive and/or replicate in phagocytic cells
SUMMARY OF THE INVENTION
when comvared to the wild tvve strain.
It is an object of the present invention to provide a
A "promoter" is a DNA sequence that directs the tranD-alanine racemase mutant mycobacteria which can be used
scription of a structural gene. Typically, a promoter is
in development of treatments for diseases caused by patholocated in the 5' region of a gene, proximal to the transcripgenic mycobacteria.
tional start site of a structural gene. If a promoter is an
inducible promoter, then the rate of transcription increases in
Accordingly, in one aspect of the present invention, a
response to an inducing agent. For example, a promoter may
novel mycobacterial strain, comprising a D-alanine racemase mutant which is not dependent on D-&nine for 20 be regulated in a tissue-specific manner such that it is only
growth, designated alrA mutant, is provided. The mycobacactive in transcribing the associated coding region in a
specific tissue type(s).
terial strain is generated from a pathogenic mycobacteviurn.
Any pathogenic mycobacteria may be used in accordance
In contrast, the rate of transcription is not generally
with the present invention. Preferred pathogenic mycobacregulated by an inducing agent if the promoter is a constiteria are M. tubevculosis, M. bovis, and all subspecies of M. 25 tutive promoter. The promoter may be tissue-geneal, also
avium.
known as non-tissue-preferred, such that it is active in
transcribing the associated coding region in a variety of
In another aspect of the invention, a live-attenuated vatdifferent tissue types.
cine against pathogenic mycobacteria is provided which
It has been discovered that the M. smegmatis alrA gene
includes the alrA mutant, with or without additional mutations. In one embodiment of this aspect, the alrA mutant 30 can be insertionally inactivated to generate AlrA null
mutants. Unexpectedly, the inactivation of the alrA gene in
displays increased susceptibility to an antimycobacterial
M. smegmatis mutant did not result in a growth requirement
agent. In a second embodiment, the alrA mutant displays
for D-alanine. Given the conservation of basic processes
increased susceptibility to bacterial action of phagocytic
within the genus Mycobactevium, a similar outcome cane be
cells. In a third embodiment, the mutant is a D-alanine
35 expected in all mycobacterial species. PCR and Southern
dependent pathogenic mycobacteviurn.
blotting analyses of w i l d - t ~ ~and
e mutant strains confirmed
In a further aspect of the present invention, methods for
the inactivation of the alrA gene in TAM20 and TAM23 by
producing live-attenuated vaccines including the alrA
gene replacement via a double-crossover event between the
mutant are provided.
M. smegmatis chromosome and the linear fragment carrying
In another aspect of the invention, a method for screening
40 the inactivated gene. Thus, alrA mutants are viable and can
antimycobacterial agents that are synergistic with peptigrow in medium without D-alanine. Complementation of the
doglycan inhibitors is provided.
alrA mutant strain with a wild-type alrA copy restores the
In yet a further aspect of the invention, a method
wild-type phenotype, indicating that properties of the mutant
new pathways
D-alanine biOs~nthesisis prostrain are due to the inactivation of the alrAgene rather than
vided. The pathways
identified may be used
45 a polar effect on the expression of a downstream gene. The
new drugs that target peptidog1ycan biOs~nthesisin myc0independence of M, smegmatis alrA mutants of D-alanine
bacteria and to identify new vaccines useful against pathofor growth indicates that this mutation does not impose an
genic mycobacteria.
auxotrophic requirement for D-alanine. This phenotype has
significant impkcations for the synthesis of D-alanine and
DETAILED DESCRIPTION OF THE
so peptidoglycan in M. smegmatis and for other mycobacterial
INVENTION
species.
D-Alanine is an essential component for bacteria with a
The present invention is directed to D-alanine racemase
peptidoglycan layer structure. The essentiality of D-alanine
mutants of mycobacterial species. The D-alanine racemase
stems from the key role of the dipeptide D-alanyl-D-alanine
gene (alrA) is involved in the synthesis of D-alanine, a basic
component of peptidoglycan that forms the backbone of the ss in the cross-linking of peptidoglycan strands (Strominger,
bacterial cell wall. The present invention is also directed to
1962). The repeating unit of the peptidoglycan from M.
methods of making live-attenuated vaccines against pathosmegmatis has a D-alanine moiety (Petit et al., 1969), and
genic mycobacteria using such alrA mutants and to the
D-alanyl-D-alanine is the only product detected in a biovaccines made according to such methods. The present
chemical assay using partially purified extracts of M. smeginvention is further directed to use of alrA mutants in 60 matis D-alanine ligase (Peteroy et al., 2000). These propermethods for screening antimycobacterial agents that are
ties support the hypothesis that D-alanine is also an essential
synergistic with peptidoglycan inhibitors. Finally, the
component for M. smegmatis . In the context of this
present invention is directed to methods to identify new
hypothesis, the independence of alrA mutants of D-alanine
pathways of D-alanine biosynthesis for use in developing
for growth suggests that M. smegmatis may have alternative
new drugs targeting peptidoglycan biosynthesis in myco- 65 pathways for the biosynthesis of D-alanine. Listeria
bacteria and to identify vaccines useful against pathogenic
monocytogenes, for example, has been shown to possess
such metabolic routes (Thompson et al., 1998).
mycobacteria.
A

a.
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As described in further detail herein, alrA mutant myco-

bacteria can be used to develop safe live-attenuated vaccines
TABLE 1-continued
of pathogenic mycobacteria, screen for drugs that act synStrains and plasmids
ergistically with peptidoglycan inhibitors, and identify new
pathways of D-alanine biosynthesis. In summary, the s strain or
Source or
D-alanine independent phenotype of M. smegmatis alrA
plasmid
Relevant characteristics
reference
mutants suggests that M. smegmatis has another pathway of
D-alanine biosynthesis, Given the conservation of basic
Air-KanR, M. smegmatis
mutant
This
derived from mcZISS
physiological processes, this finding is of significance for
M, ,egmatis
A ~ ~ - K M,
~ ~smegmatis
R,
mutant
n i s study
derived from mcZ1S5
pathogenic mycobacteria and the design of novel attenuated 10 TAM23
strains and antimycobacterial agents.
M. smegmatis
Alr+HygRKanR,M. smegmatis alr mutant This study
TAM23
complemented with wild type gene
Method of Use: Development of Novel alrA Mutant
(pTAMU3)
integrated at the mycobacteriophage LS
Mycobacterial Strains
attB site
KanR , recombinant plasmid carrying the (5)
pBUNs2
Novel alrA mutant pathogenic mycobacterial strains can
alr gene from M. smegmatis mcZISS in a
be generated in accordance with the present invention. The
1.9 kb BamHIIPvuII fragment
pBluescript
AmpR, standard E. coli cloning vector
Stratagene
generation of alrA mutants has been illustrated by preparaKS
tion of M. smegmatis alrAmutants. However, other methods
AmpR, pBluescript I1 KS + with
This study
pTAMU1
known in the art may be used to generate stable alrAmutants
the 1.9 kb BamHIIPvuII fragment of
such as chemical mutagenesis followed by mutant
pBUN82 in the BamHIIEcoRV site
AmpR KanR, pTAMUl with the
This study
enrichment, transposon mutagenesis, plasmid or phage 20 pTAMU2
1.24 kb P S ~ aph
I fragment of pUC4K
vectors, and methods to produce unmarked in-frame dele(Pharmacia, Inc. Piscataway, N.
tions. The same procedures described herein may be used to
J.) in the PstI site
inactivate the alrA gene of other pathogenic mycobacterial
pTAMU3
AmpRHygR,pYUB412 with the
This study
1.9 kb BamHIIPvuII fragment of pBUN82
species in order to generate alrA mutants of such species.
in the BC~IIECORV
site
Such species of mycobacteria include Mycobacteviurn 2s
AmpRHygR,E. coli-Mycobacterium
(33)
pYUB412
tubevculosis, Mycobactevium avium, Mycobactevium bovis,
mtegratlon-proficient vector. Integrates
Mycobacteviurn afvicanum, and Mycobactevium pavatubevat the mycobacteriophage LS attB site
culosis To inactivate the alrA gene in M. smegmatis, a DNA
fragment carrying the wild-type gene was subcloned into the
To determine whether these transformants carry an inacE. coli cloning vector pBlue-script I1 KS(+) to yield the
tivated
alrA gene, genomic DNA was isolated and amplified
recombinant plasmid pTAMUl (Table 1). Then, the 1.2-kb
by PCR. As expected for the inactivation of the alrA gene,
kanamycin resistance determinant from plasmid pUC4K
genomic DNA from both TAM20 and TAM23 yielded the
containing the aminoglycoside 3'-phos-photransferase type
2.4-kb product. Southern blotting analysis was used to verify
I-coding gene from transposon Tn903 (30) was inserted at
the occurrence of these recombinational events in the approthe unique PstI site internal to the alrA gene. The resulting
priate M. smegmatis strains. Genomic DNA was isolated;
construct, pTAMU2, carries an insertionally inactivated alrA
digested with SmaI, which cuts once within the alrA gene;
gene, which can be excised as a linear 3.2-kb BamHI-kvnl
transferred to a membrane; and hybridized with the wildfragment (Table 1). Based on the hypotheses that D-alanine
type alrA gene fragment as a probe. The wild-type strain
is an essential component and that AlrA is the only enzyme
mc2155 gave two homologous bands of approximately 15.0
responsible for D-alanine biosynthesis in M. smegmatis, it
and 1.8 kb, whereas TAM20 and TAM23 yielded a mutantwas predicted that an alrA mutant would be dependent on
type pattern with three bands of approximately 15.0,2.2, and
D-alanine for growth. Unexpectedly, the inactivation of the
1.2 kb. These patterns were as expected for the predicted
alrAgene in M. smegmatis mutant did not result in a growth
recombinational events, validating the construction of the
requirement for D-alanine. The step to select for this mutant
strains described herein.
was carried out in MADC agar supplemented with 50 mM
The identification of only one D-alanine racemase gene in
D-alanine in addition to 20 ug of kanamycin per ml. Transthe mycobacterial genome sequencing projects suggests that
formation of M. smegmatis mc2155 with the 3.2-kb linear
M. smegmatis alrAmutants may be dependent on exogenous
fragment carrying the inactivated alrA gene yielded 25
D-alanine for growth. Both mutant strains, TAM20 and
kanamycin-resistant transformants, and 2 of these, desigTAM23,
exhibited wild-type growth in MADC agar supplenated TAM20 and TAM23, were further analyzed.
mented with D-alanine, giving rise to typical flat-border
colonies after 3 days of incubation at 3 7 ~ : i n the absence of
TABLE 1
D-alanine, TAM20 and TAM23 cells were also able to grow,
but colonies displayed a drier appearance with more raised
Strains and plasmids
ss borders. Complementation of TAM23 with the integrating
Strain or
Or
construct pTAMU3 introduces a wild-type alrA gene at the
plasmid
Relevant characteristics
reference
mycobacteriophage L5 attachment site (Lee and Hatfull,
E. coli DHSa
F-lacZDM1S endAl hsdRl7 supE44
Invitrogen
1993; Pascopella, 1994) and fully restores wild-type colony
gyrA96 relAl
Life
morphology. Except for these differences in colony
Tech60 morphology, no other observable differences were detected
nologies
E. coli
D(rncrA)183 D ( r n c r C B - h S d ~ ~ ~ - r n r r ) l Stratagene
73
by light Or electron microscopy when cells were grown in
XL2-Blue MRF' endAl supE44 thi-1 recAl gyrA96
the presence or absence of D-alanine. Bacilli from both
relAl lac [F' proAB lacIqZDM1S
wild-type and mutant strains were weakly gram positive,
TnlO TetR CamR]
acid fast, and displayed the same aspect of elongated rods.
M. smegmatis
Alrf, high efficiency plasmid
(37)
65 Likewise, at the ultrastructural level, cells did not differ in
mcZ1Ss
transformation mutant of M. smegmatis
mcZ6
either shape, size, or thickness of the cell walls. In summary,
M. smegmatis alrA mutants are independent of exogenous

matis is

"

+

have been reviewed (Pelicic et al., 1998). Using conditionD-alanine, a property that was further confirmed by their
ability to grow in MADC, as described more frilly herein,
ally replicating genetic elements, two groups have reported
and minimal broth containing mineral salts, glycerol, pyrimajor breakthroughs in the genetic manipulation of M.
doxal phosphate, and Tween 80.
tubevculosis (Bardarov et al., 1997; Pelicic et al., 1997).
To determine whether M. smegmatis alrA mutants are or s Methods to generate unmarked deletion mutations in M.
are not devoid of Alr activity, crude cell extracts from
smegmatis, BCG, and M. tubevculosis have been described
wild-type and mutant strains were prepared and assayed for
(Pavelka &Jacobs, 1999). This technology coupled with the
enzyme activity. Protein extracts prepared from wild type
knowledge of the M. tubevculosis genetic blueprint (Cole et
mc2155 cells grown in the presence or absence of D-alanine
al., 1998) should provide novel strategies for the rational
displayed approximately equal levels of Air activity that 10 development of live attenuated vaccines. The most promismatched the specific activities previously reported ( ~ a c e r e s ing approach for vaccine development would be to start with
virulent M. tubevculosis microorganisms and generate
et al., 1997). In contrast, extracts from TAM23 prepared
attenuated mutants. These mutants should carrv at least two
from cells grown in the presence or absence of D-alanine
attenuating deletion mutations and no antibiotic resistant
lacked any detectable Alr activity. These extracts yielded
background levels of Alr activity not significantly different IS markers, so as to avoid unwanted reversions or transfers of
drug-resistance. It is contemplated that vaccine strains genfrom the levels obtained by replacing bovine serum albumin
erated by the method of the present invention will include
for TAM23 extracts in the reaction mixture. This absence of
one or more additional mutations. Other imaortant issues to
Alr activity in TAM23 extracts was not clue to the presence
consider are a) the degree of attenuation: mutants that are too
of an inhibitor since mixtures of TAM23 and mc2155
extracts gave the Air activity proportional to the amount of 20 attenuated may not induce protective immunity as it was the
case for S. typhimuvium phoP mutants (Fields et al., 1989);
enzyme present in the active extract from the wild-type
and b) whether the effect of the vaccine strain could be
strain. Furthermore. to rule out the aossibilitv that sonic
potentiated by co-administration of cytokines or by endowdisruption may have damaged more readily protein extracts
ing the engineered strain with the capability to produce
of potentially fragile TAM23 cells, LDH activity was also
measured. The M. smegmatis LDH activity was found to be 25 cytokines or phagosome membrane disrupters as lysteriolysin. In this case, temporal expression of these genes may be
more sensitive to prolonged sonic disruption and provides a
critical and may have to be regulated by promoters solely
useful control to determine whether TAM23 extracts are
active inside phagocytic cells, as for example the promoter
enzymatically active. In contrast to the results obtained in
of the mig gene, first identified in M. avium (Plum &
the Alr assay, extracts from both mc2155 and TAM23
displayed similar levels of LDH activity above background 30 Clark-Curtiss, 1994) with a corresponding homologue
(fadD19) found in the M. tubevculosis genome sequence
levels. Furthermore, complementation of TAM23 with a
(Cole et al., 1998).
wild-type air gene restored Alr activity. Thus, it was conCandidate genes for attenuating mutations may be those
cluded that inactivation of the alrA gene results in no
directly involved in the pathogenic process or those encoddetectable Alr activity in the M. smegmatis alrA mutant
strain.
35 ing housekeeping enzymes whose suppression may alter the
ability of M. tubevculosis to survive and/or replicate within
Method of Use: Generation of Live-Attenuated Vaccines
phagocytes. The best documented examples of mutations
An ideal vaccine against diseases caused by mycobacteria
leading to attenuated phenotypes in vivo are the inactivasuch as tubevculosis, leprosy, and Crohn's disease in humans
tions or deletions of the M. tubevculosis genes erp (Berthet
and Johne's disease in dairy cattle should be able to protect
against the widest possible range of pathogenic bacterial 40 et al., 1998), hma (Dubnau et al., 2000), katG (Li et al.,
1998), leuD (Hondalus et al., 2000), mgtC (Buchmeier et al.,
isolates eliciting a strong CMI requiring presentation of both
2000), and the recently described cyclopropane synthetase
peptide and non-peptide antigens, long-lasting immunologigene pcaA (umaA2) involved in cord formation (Glickman
cal memory, and possibly humoral immunity. Given this
et al., 2000), and purC (Jackson et al., 1999). In addition, a
complexity, live attenuated vaccines may offer the best
possibilities for an ideal antimycobacterial vaccine. 45 M. tubevculosis deletion mutant unable to synthesize mycobactin was generated and shown to be impaired for growth
Furthermore, this type of vaccine could potentially be
in a human macrophage cell line (De Voss et al., 2000).
administered orally as enteric-coated lyophilized tablets,
Additional candidate genes and previous work has been
thus avoiding the use of needles (Barletta et al., 1990).
summarized elsewhere (Cole et al., 1998). Other candidates
Additionally, a live attenuated vaccine could even be made
compatible with current or experimental new diagnostics SO are unidentified mycobacterial genes such as those involved
in the inhibition of phagosome acidification (Sturgill(Cirillo et al., 1995). Although recent studies with subunit
Koszycki et al., 1994; Via et al., 1998). It may be also
vaccines have been promising, so far these vaccines conpossible to identify and inactivate genes responsible for
ferred shorter survival than BCG when tested in M. tubevsubtle changes in the structure of lipoarabinomannan since
culosis aerogenically challenged guinea pigs, underlying the
problems to be solved with these types of vaccines (Baldwin 55 these changes influence receptor-mediated uptake and ultimately intracellular fate and overall virulence (Kang &
et al., 1998). However, subunit vaccines also may be imporSchlesinger, 1998). Another approach that has been foltant for disease control in immunodeficient individuals or in
lowed for the attenuation of M. tubevculosis is to engineer a
areas where the standard skin test has diagnostic signifirecombinant strain overexpressing a global negative regucance. Furthermore, a subunit vaccine may be useful to
boost individuals previously vaccinated with BCG or those 60 lator of virulence genes. In this context, it was found that a
recombinant M. tubevculosis carrying a dominant constituat risk of disease reactivation (Baldwin et al., 1998).
tively active iron repressor was attenuated in mice (Manabe
The generation of a new live-attenuated vaccine poses
et al. 1999). The above literature also describes standard
many research challenges. Genetic systems to manipulate M.
methods for testing candidate vaccine strains in animal
bovis BCG and M. tubevculosis offer the greatest promise for
the development of new and effective vaccines against 65 model systems such as mice or guinea pigs.
It was discovered that M. smegmatis alrAmutants display
mycobacterial infections. Methods for allelic replacement
an increased susceptibility to bactericidal action of phagoand transposon mutagenesis in slow-growing mycobacteria

cytic cells such as macrophages (Chacon, O., 2002, incorinfection. Nonetheless, the effect is minor and significantly
porated herein by reference.) Based on this finding, pathodifferent from the complete recovery of the survival of
genic species of mycobacteria having an inactivated alrA
TAM23 conferred, at every time-point post-infection, by the
gene could be constructed using methods known in the art.
hygromycin-resistant integrating vector pTAMU3 carrying
Such strains would be useful for the generation of attenuated s the wild type gene.
Method of Use: Identification of New Antimycobacterial
live-attenuated vaccine candidates against tubevculosis and
Agents
other human or animal diseases caused by mycobacteria
In addition to new effective vaccines against
such as leprosy and Crohn's disease and Johne's disease.
a
Further, based on the discovery that alrA mutants are
mycobacteria, there is also an urgent need to develop new
impaired in the ability to synthesize the basic building block 10 antimycobacterial agents. These new agents should be effecof cell walls, peptidoglycan, vaccine strains which undergo
tive against these microorganisms without being toxic to the
spontaneous lysis in vivo can be constructed using methods
mammalian host. Drug therapy is the major approach to treat
known in the art. Lysis would allow for improved antigen
human mycobacterioses. Several primary and secondary
delivery and containment of the vaccine strain.
anti-mycobacterial agents are currently used to treat human
To determine the effect of the inactivation of the alrAgene IS tubevculosis. The Food and Drug Administration has
approved the following drugs as primary agents:
on the intracellular survival of M. smegmatis in phagocytic
ethambutol, isoniazid, pyrazynamide, rifampin, and strepcells, monolayers of human macrophages were infected with
tomycin. Examples of approved second-line drugs are:
wild type, mutant and recombinant control strains. Prior to
amikacin, ciprofloxacine, cycloserine, ethionamide, and
infection, M. smegmatis strains were grown in medium
supplemented with D-alanine which results in approxi- 20 para-aminosalicylic acid. Recommended treatments use
combination therapies with three agents for at least six
mately the same rate of growth for all strains. Growth in
months. However, these regimens are becoming ineffective
monolayers was carried out in absence of D-alanine to
due to the emergence of drug resistance strains, including
approximate the conditions expected in the host. Monolayers were infected with M. smegmatis strains at a multiplicity
the appearance of clinical isolates with multiple resistances
of approximately 10 bacilli per cell, invasion was allowed to 25 to various primary and secondary drugs (Edlin et al., 1992;
proceed for 2 h and extracellular bacteria were removed. At
Kochi et al., 1993; Musser & Barry 1998). Thus, there is an
24, 48 and 72 h post-infection, the number of intracellular
urgent need to develop new and more effective antisurviving bacteria was determined as described in Materials
tubevculosis drugs.
Recent studies on mycobacterial drug resistance have
and Methods. As expected, the wild type strain mc2155
displayed moderate survival in monolayers of adherent 30 focused on the study of specific biochemical targets of the
primary and secondary drugs (Musser et al., 1999). For a
human macrophages, with about 5-fold reduction in the
summary of the principal targets identified to date, see
number of intracellular bacteria after 72 h of incubation of
Chacon, Ph.D. Thesis 2002, incorporated herein in its
the monolavers. In contrast. the alrA mutant strain TAM23
entirety. In all these cases, the common theme is that these
was less able to survive reaching a 5-fold reduction in
intracellular bacilli at 24 h and 500-fold by 72 h. Thus, the 35 targets are enzymatic proteins involved in key metabolic
inactivation of the alrA gene has a significant effect on the
processes for the Mycobacteviurn. Identification and bioability of M. smegmatis to survive within phagocytic cells.
chemical analysis of these proteins is then applied to the
To verifv that the decreased survival of the mutant strain
rational design of new and more effective anti-mycobacterial
was due to the inactivation of the alrA gene, M. smegmatis
agents (Zhang & Telenti, 2000). Furthermore, genes encodTAM23 was complemented with a wild type copy which 40 ing for some of these proteins may also serve as targets for
was delivered into the chromosome using an integrating
the generation of attenuated strains that could be useful in
vector. Strain TAM23(pTAMU3), carrying both the inactideveloping effective vaccines against mycobacteria. This
might be the case with genes playing an important role in
vated and wild type copies of the alrA gene, displayed wild
metabolic pathways that are necessary for the biosynthesis
type survival in human macrophages. This result confirmed
that the inactivation of the alrA gene is responsible for the 45 of mycobacterial structural components. One of these genes,
reduced survival of TAM23. In addition, the effects of
involved in the biosynthesis of peptidoglycan, is the alrA
introducing selection markers on the survival of M. smeggene. The present invention is equally applicable to other
matis in phagocytic cells were tested using appropriate
mycobacterial genes involved in the synthesis of D-alanine.
recombinant control strains. The kanamycin-resistant
The inhibition of AlrA by DCS in a concentrationmarker used to inactivate the alrA gene was introduced into so dependent manner indicates that this enzyme serves as one
the chromosome of the wild type strain via an integrating
of the drug targets (Caceres et al, 1997). However, the
vector. The resulting recombinant strain mc2155(pYUB178)
dispensability of the alrA gene for growth in vitro suggests
displayed the same survival pattern as the wild type strain
that it is not the main target responsible for the bactericidal
indicating that the introduction of this marker does not affect
effect of DCS. Since overproduction of the enzyme leads to
the intracellular survival of M. smegmatis. Since the vector ss increased resistance to DCS, it appears that binding of DCS
to AlrA protects another target within the cell. This hypothused to complement the mutant strain carries a hygromycinesis predicts that AlrA null mutants would be hypersuscepresistant marker, strain TAM23 was also transformed with
tible to DCS. Thus, the corresponding MICs for wild-type
this vector alone to generate the recombinant alrA mutant
and TAM23 alrA mutant strains were determined.
strain TAM23(pYUB412). In this case, the survival of this
For MIC tests, M. smegmatis cells grown with and
recombinant strain was slightly affected by the introduction 60
without n-alanine were inoculated onto complete Middleof this marker. At 24 h post-infection, both TAM23 and
TAM23(pYUB412) displayed a 5-fold reduction in intracbrook MADC broth without D-alanine. The MIC of DCS for
the wild-type strain was 75 pglml, independent of the
ellular survival; however at 48 and 72 h post-infection,
TAM23(pYUB412) displayed an intermediate level of surpresence of D-alanine in the original inoculum (Table 2). As
vival when compared to the wild type and TAM23 mutant 65 expected, TAM23 was about 30-fold more sensitive (MIC,
2.56 pglml) when the inoculum was grown without
strains. (FIG. 4). Thus, the hygromycin resistant marker has
an influence on intracellular survival at longer times postD-alanine. Since TAM23 cells carry a mutation in a gene
u
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responsible for D-alanine biosynthesis, it is possible that
growth in the presence of D-alanine partially restores wildtype MICs of DCS. To test this hypothesis, TAM23 was
grown with D-alanine, harvested, washed extensively to
prevent D-alanine carryover, and inoculated into the MIC
test cultures. These conditions resulted in a fourfold increase
in the MIC (MIC, 10.2), still about 7.5 times lower than the
MIC for the w i l d - t ~ ~strain.
e
As a control, the MICs of the
unrelated drugs amikacin, ethambutol, and rifabutin were
also determined. The MICs for both w i l d - t ~ ~and
e mutant
strains were the same, independently of the Presence or
absence of D-alanine in the medium used to grow the
inocula to determine the MICs. The effect of the addition of
D-alanine directly into the MIC test cultures was also
determined. D-Alanine would be expected to effectively
compete with DCS and decrease the susceptibilities of both
strains to DCS. As expected, under these conditions, the
MIC of DCS for both w i l d - t ~ ~and
e TAM23 strains
increased dramatically to 1,200~glml
independently of prior
growth conditions of the inocula. No significant differences
were observed for the other unrelated drugs, demonstrating
that the effect was specific for DCS. Complementation of
strain TAM23 with the integrating vector pTAMU3, which
carries the wild-type air gene, resulted in a strain for which
the MICs were identical to those for the wild type.

However, it must be emphasized that considering absolute
drug concentrations, the effect on the mutant strain is
observed at a 30-fold-lower concentration than for the
wild-type strain. This pattern suggests that the bactericidal
,,tion of DCS is due to the inhibition of a more fundamental
target different from d r ~ ,
An alternative explanation for the increased susceptibility
of the null mutants to DCS is that the inactivation of the alrA
gene changes the permeability of the cell wall to DCS, m i s
alteration may not be detectable by morphological studies.
To test this hypothesis, a methodology to perform DCS
uptake assays was developed. The results obtained were
similar for both wild-type and mutant strains, ~
~
uptake assays using a standardized procedure obtaining
similar results for both strains was also carried out. Thus, a
permeability change was ruled out as responsible for the
observed phenotype of the null mutants,
The uptakes of D-alanine and DCS in both wild-type and
mutant strains were not significantly different, indicating
that changes in cell wall permeability are not a likely
explanation for the DCS increased susceptible phenotype of
the alrA mutant strain. Thus, the increased susceptibility of
T - 2 3 cells to DCS is consistent with the existence of
multiple targets for DCS, our previous studies identified
D-alanine racemase as one of these targets (Caceres et al,
1997). The lack of the racemase protein in the alrA mutant
strain may lead to a hypersusceptible phenotype since more
DCS would be required to inhibit both the racemase and an
additional target(s) in the wild-type strain. In contrast, the
bactericidal effect of DCS suggests the existence of another
lethal target. In this context, D-alanine ligase is an attractive
candidate since this enzyme activity is also inhibited by
DCS (David, 1969; Chacon, Ph.D. thesis). More
importantly, the construction of a conditionally lethal mutant
bank led to the isolation of a thermosensitive mutant
impaired in this gene function
et al,, 2000).
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TABLE 2
Minimal inhibitory concentrations of M. smegmatis wild type and
TAM23 alr mutant strains to selected antimycobacterial agents
determined with inocula grown with or without D-alanine.

30

Minimal Inhibitorv Concentrationa (MIC, ~ g l m l )
Wild Tvpe mcZ 155

Drug

Without
D-alanineb

With
D-alaninec

TAM23 alr Mutant
Without
D-alanineb

With
35
D-alaninec

Furthermore, increased DCS susceptibility may reflect an
alteration of the vevtidonlvcan
structure of TAM23 cells. as
u ,
a direct consequence of the inactivation of the alr gene. In
40 this context, TAM23 cells were also more susceptible to
DCS than were wild-type cells when grown in medium with
aMICs were determined in complete Middlebrook 7H9 medium as
described in Materials and Methods. For a given drug, MIC differences of
D-alanine, but mutant cells grown without D-alanine disthe two strains are considered significant when values correspond to a
played increased susceptible to both growth inhibition and
separation of at least two doubling dilutions.
the bactericidal action of DCS.
b~noculumwas grown in complete Middlebrook 7H9 medium without
45
Based on the finding that inactivation of the alrA gene of
D-alanine supplementation, as described in Materials and Methods.
CInoculum was grown in complete Middlebrook 7H9 medium suppleM. smegmatis yielded a strain with increased susceptibility
mented with 50 mM D-alanine, as described in Materials and Methods.
to D-alanine analogs, the generation of Alr null mutants as
vaccine candidates would be possible using methods known
This increased susceptibility indicated by the MIC growth
in the art. The present invention accordingly seeks to proinhibition data was also confirmed by the analysis of the
bactericidal action of DCS in broth cultures grown in SO vide novel live-attenuated mycobacteria as vaccines. Such
absence of D-alanine. Pilot experiments were performed
vaccines would be especially effective for treatment of
with each strain to determine the optimal DCS concentration
immunosuppressed patients, or others displaying signs of
that resulted in a strong bactericidal effect. In the final
disease, with drugs such as D-alanine analogs.
experiment, cultures were grown to an early exponential
Method of Use: Use of D-Alanine Racemase Mutants to
phase (OD,,, of -0.4), split in two, and DCS was added to ss Identify New Pathways of D-Alanine Biosynthesis
one of these subcultures at 50 times the MIC. In absence of
It was discovered that M. smegmatis D-alanine racemase
DCS, both the wild-type strain mc2155 and the TAM23
mutants can synthesize D-alanine by verifying the presence
of D-alanine within the internal amino acid pool of TAM23.
mutant cells grew to a OD,,, of >2.0 and reached saturation
at a cell density approximately above 5 . 0 ~ 1 0 These
.
data
To determine the gene(s) responsible for the alternative
also confirmed the independence of M smegmatis air 60 pathway of D-alanine biosynthesis, the following procedure
mutants on D-alanine for growth and further demonstrate
is followed: 1) a transposon mutant bank of TAM23 is
constructed, 2) mutants are screened for the ability to grow
that air mutants can grow in absence of D-alanine at approximately the same growth rate as wild-type cells. In contrast,
in the presence or absence of D-alanine in the growth
in the presence of DCS both cells underwent rapid death by
medium, 3) mutants unable to grow in the absence of
lysis as revealed by both the drastic decrease observed in 65 D-alanine are identified by replica, 4) the region containing
optical density and viable counts. Furthermore, the kinetic of
the transposon is cloned, and 5) the gene inactivated by the
killing was similar for both the wild-type and mutant strains.
transposon is identified by DNA sequencing. Alternatively,
Amikacin
D-Cvcloserine
~thahbutol
Rifabutin

1.56
75.0
3.13
2.00

N.D.
75.0
N.D.
N.D.

1.56
2.56
3.13
2.00

1.56
10.2
3.13

..

-

l

~

~

i

~
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a proteomic analysis of TAM23 can be performed before and
1.0~10-5 mM manganese chloride, 16 mM monobasic
after a shift from medium with D-alanine to media without
potassium phosphate, 4 . 9 ~ 1 0 - 6 mM p y r i d o x a l
D-alanine. Proteins induced under the latter conditions are
hydrochloride, 0.4 mM Tween 80, and 8.6~10-6mM zinc
candidates for enzymes involved in an alternative pathway
sulfate. Individual chemicals were purchased from Sigma.
of D-alanine biosynthesis. Protein spots are sequenced, and s
~ ~ ~transformation,
t ~ ~ E, icoli~wasl transformed as prethe coding
are identified and then inactivated to
viously described (Ausubel et al., 1990). For the generation
construct strains carrying multiple mutations. These strains
. f ~ ,smegmatis alr~mutants,
50 of an early exponential
are evaluated for their dependency on D-alanine for growth.
phase culture of M, smegmatis mc2155 was washed twice
Based on the finding thatTAM23 mutant of M. smegmatis
and concentrated 100-fold in cold 10% ultrapure glycerol
was independent of D-alanine for growth, the inactivation of 10 it^^^^^ if^ ~ ~ ~ hcarisbad,
~ ~calif,),
l ~concen~ i ~
the
gene provides a means to study alternate metabolic
trated cells were electroporated with approximately 5.0pg of
pathways related to ~ e ~ t i d o g l ~ synthesis
can
in pathogenic
the BamHI-KpnI fragment of pTAMU2 carrying the inacm~cobacteria.The discovery that m~cobacteriaPossess a
tivated alrA gene. Electroporation was carried out at 2,500
novel pathway of ~ e ~ t i d o g l ~ synthesis,
can
makes possible
V. 100 pF, and 246 Q in an electrocell manipulator (model
the exploitation, using methods known in the art, of such in 1s 600; BTX Inc., San Diego, Calif.). Electroporated cells were
the generation of other attenuated strains and new antimyallowed to recover at 3 7 in~ MADC broth and plated on
cobacterial drugs. The present invention accordingly seeks
MADC agar supplemented with 50 m~ ~
~(sigma)
l
~
~
to provide novel AlrA null mutant mycobacterial strains for
and kanamycin (20 pglml; sigma), F~~the genetic cornpieuse in determining alternate metabolic pathways of
mentation experiment, 50 ml of an early-exponential phase
t electropoD-alanine andlor peptidoglycan biosynthesis in the identi- 20 culture of^, smegmatis T - 2 3 a l r ~ m u t a nwas
fication of drug targets for development of new bactericidal
rated with 1.5 mg of p
~ DNA at~ 2,500 V,
~ 25 p ~3and
,
agents for the treatment of mycobacterial diseases.
1,000 Q in a Gene Pulser electrocell manipulator (Bio-Rad
Method of Use: Use of a DCS H ~ ~ e r - S u s c e ~ t iMutant
b l e to
Laboratories, Richmond, Calif.), as previously described
Screen for Cell Wall Inhibitors
(Foley et al., 1995). Transformants were selected on MADC
An alrA mutant can be used to screen for inhibitors of 25 agar supplemented with hygromycin (100 pglml; ~ ~ ~ h ~
peptidoglycan synthesis following methods known in the art
Nucleic acid manipulations, Mycobacterial DNA was
(KamOgashira and Takegata, 1988,
herein
isolated by the standard method using cetyl trimethyl ammoreference).
nium bromide (Ausubel, 1990). Plasmid DNA was isolated
by an alkaline lysis method as previously described
EXAMPLES
30 (Sambrook, 1989), using a large-scale isolation kit
The present invention is further described in the following
(promega, ~ ~ dwis,)
i as~ recommended
~ ~ , by the manuexamples, which are offered by way of illustration and are
facturer. DNAfragments used for plasmid construction in E.
not intended to limit the invention in any manner. Standard
coli and for recombination experiments in M, smegmatis
techniques well known in the art or the techniques described
were purified by gel e~ectrop~oresisand recovered by
below are utilized in the practice of the present invention. 35 absorption to glass particles (
G
~ ~i~
~ 101,
~ vista,
c
~
~
Calif.) as recommended by the manufacturer. Standard proExample 1
cedures were followed for restriction digestions, ligations,
and agarose gel electrophoreses (Sambrook, 1989).
Generation of M. smegmatis alrA Mutants
Amplification of the alrAgene was carried out with 50 ng
Bacterial strains, plasmids, and culture conditions. Bacof M. smegmatis genomic DNA template using primers
terial strains and plasmids used in this study are listed in
NAN-1 and NAN-2 for 27 cycles in a thermal cycler
Table 1. E. coli strains were grown at 37C in Luria-Bertani
(Perkin-Elmer Gene Amp PCR System 2400; Roche
broth or agar. M. smegmatis strains were routinely grown at
Molecular Systems, Branchhurg, N.J.) as previously
37C in Middlebrook 7H9 base broth or agar (BBL Microdescribed (Caceres, 1997). For Southern blotting analysis,
biology Systems, Cockeysville, Md.) supplemented with
approximately 3.0 pg of M. smegmatis genomic DNA was
0.5% bovine serum albumin fraction V (EM Science,
digested with SmaI, and DNA fragments were separated on
Gibbstown, N.J.), 0.01 M dextrose (Sigma Chemical Co., St.
a 0.8% agarose gel, subjected to an alkaline denaturing
Louis, Mo.), 0.015 M sodium chloride, and 0.2% glycerol
procedure, and transferred to Biotrans nylon membranes
(MADC). Broth medium was also supplemented with 0.05%
(ICN Biomedicals, Inc., Costa Mesa, Calif.). Membranes
Tween go (Sigma), and solid medium was made with 1.5%
were hybridized with a probe corresponding to the 1.9-kb
Bacto Agar (Difco Laboratories, Detroit, Mich.). When
BamHI/PvuII fragment containing the wild-type M. smegrequired, 0-alanine (Sigma) was used at 50 mM. Liquid
matis alr gene, which was radiolabeled with [a-32PldCTP
cultures were incubated with shaking at 200 rpm in an
using the Rediprime DNA labeling I1 system (Amersham
Innova 4300 rotary incubator (New Brunswick Scientific
Pharmacia Biotech, Inc., Piscataway, N.J.) as recommended
Co. Inc., Edison, N.J.). As needed, the following antibiotics
by
the manufacturer. Prehybridization and hybridization
were used at the specified concentrations: ampicillin
were performed at 56C. Washes were done under high(Sigma), 50 pglml for E. coli; kanamycin A monosulfate
stringency conditions at 65C as previously described
(Sigma), 25 pglml for E. coli and 20 pgiml for M. smeg(Sambrook, 1989).
matis; hygromycin B (Roche Molecular Biochemicals,
Gram staining and acid-alcohol resistance testing. M.
Indianapolis, Ind.), 100 pglml for E. coli and M. smegmatis.
smegmatis cells were stained by the crystal violet method
For some experiments, M. smegmatis was grown in a broth
using a Gram stain kit (Sigma) as recommended by the
minimal medium based on the formulation of Zygmunt,
manufacturer. Acid-alcohol resistance was determined by
1963, as modified by Caceres, 1999. Components and final
the Zielsi-Neelsen acid-fast procedure using the TB Stain
concentrations were 5.0 mM ammonium chloride, 6.8~10-7
Kit ZN (Difco), as recommended by the manufacturer.
mM calcium chloride, 8.4~10-7mM cobalt(I1) chloride, 22
mM dibasic potassium phosphate, 2.5~10-10 mM ferric
Electron microscopy. Strains were grown to an optical
chloride, 21 mM glycerol, 2.4 mM magnesium sulfate,
density at 600 nm (OD655) of approximately 1.0 in MADC-
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Tween, with or without D-alanine. Cells were harvested,
tions. M. srnegrnatis mc2155 and TAM23 cells were grown
washed twice with phosphate-buffered saline (PBS)-0.05%
in 25 ml of MADC-Tween with and without 50 mM
Tween, and fixed for 1 h in 2.5% buffered glutaraldehyde,
D-alanine to an OD,,, of approximately 1.0. Bacteria were
washed twice, and postfixed with 2.0% osmium tetroxide.
washed with pBS-Tween, and 105 CFU was inoculated onto
After repeated washings in PBS, samples were dehydrated s each well containing serial twofold dilutions of various
in a graded series of ethanol solutions, washed twice in
antimicrobial agents, plates were incubated at 3 7 ~ and
,
propylene
and embedded with Araldite resin. 'Ihin
visual inspection to determine MICs was carried out at 48 h.
sections were examined with a Philips 201 transmission
The MIC is defined as the lowest concentration that prevents
Optics, EindhOvetn
observable bacterial growth and is determined by the conThe
at an
of 60 kV'
10 sistent result of three independent cultures, each assayed in
D-Alanine racemase assays. Approximately 200-ml cultriplicate,
tures of M. srnegrnatis mc2155 or TAM23 were grown in
M. srnegrnatis strains mc2155 and TAM23 were grown in
MADC-Tween with or without D-alanine until they reached
an OD,,, of ca. 1.0. Cultures were washed twice and
MADC-Tween
at 37C
an OD,,,
ca. 0.5. These
concentrated 50-fold in 50 m~ T ~ ~ ~ -( Hpc 8.0).
~ cells
starter cultures were used to inoculate 200 ml of MADC
broth, and cells were then grown to an OD600 of ca. 0.4. Two
were sonicated on a salt-ice-water bath with a Vibra-Cell
model VC600 sonicator (Sonic and Materials, Inc., Danbury,
50-ml aliquots of these exponentially growing cultures were
Conn.). Sonication was carried out for 2 min at 80% power
transferred to separate flasks. DCS was added to one of the
output and 50% duty cycle, and in the presence of 30%
corresponding cultures, with the other serving as a growth
(vol/vol) type A-5 alumina (Sigma). The resulting active cell
control. Concentrations of DCS were 50 times the MIC for
extracts were centrifuged at 4C in a JA-17 rotor (Beckman 20 each strain (3.75 mglml for mc2155 and 128 pglml for
Instruments, Inc., Fullerton, Calif.) for 30 mm at 15,000
TAM23). All cultures were incubated at 37C in a shaking
rPm, dialyzed against 50 mM Tris-HCl(pH 8.0), and sterilincubator for 72 h. The OD,,, was measured for each culture
ized by filtration through a 0.22-~-~oresize
filter (Advantec
at 3, 6, 9, 12, 24, 48, and 72 h. Concurrently, aliquots were
MFS Inc., Pleasanton, Calif.). Protein concentration was
taken, serially diluted, and plated onto M ~ agar
C in
determined
the DC assay (BiO-Rad) as
25 triplicate to determine numbers of viable bacterial counts.
the manufacturer. Alr activity in the active cell extracts was
assayed in the direction of the conversion of L-alanine into
Example 4
D - a l a n i n e b y a modification of the c o u p l e d D-Alanine Uptake Assays
spectrophotometric method previously described (Caceres,
1999). To start the reactions, active crude cell extracts were 30
F~~ ~
~uptake
l assays,
~
~ thei method
~
~described by
added to 1.0 ml of prewarmed mixtures containing 50 mM
David, 1971, was used, Cells exponentially growing in
Tris-HC1 (pH 8.0),
mM pyridoxal phosphate (Sigma),
MADC-Tween (OD,,,, ca, 1.0) were collected by
and 15 mM L-alanine (Sigma). After 15 min of incubation
gation at 40C, washed once in ice-cold 50 mM Tris-HC1
at 37C, when the conversion of substrate into product
buffer
(pH 8.0) containing 0.05% Tween 80, and concenremains linear, reactions were stopped by boiling for 10 min.
of d-amino acid oxidase (Calzyme, Sari 35 trated 20 times in the same buffer. Samples were prewarmed
Subsequently,
for lo
at
and D-alanine was added to a
Lois Obispo, Calif.), 0.2 mM NADH (Roche Laboratories),
3.0 pCi
[14Cl-1-D-a1anine (ICN) per
and 10 U of rabbit muscle lactic dehydrogenase (Sigma)
iumol asid 0.2 mM ~~ncentration.
Samples were placed in a
were added. The coupled reaction was measured by the
37C water bath. Aliquots were taken at various times and
change in absorbance at 340 nm after 5 h of incubation at
37C. All samples were measured in triplicate. Specific 40 immediately placed on ice. The sample for each time ~ o i n t
activities (in micromoles of consumed substrate minute-1
was divided in three subsample triplicates of 0.5 ml and
milligram-1) were calculated as previously described
filtered through 0.8-pm-pore-size membrane filters
(Caceres et al, 1997).
(Millipore Corp., Bedford, Mass.) in a manifold. Each filter
was washed three times with 10 ml of cold buffer, dried
LDH assays. L-Lactate dehydrogenase (LDH) activity
endogenous to crude cell extracts of M. srnegrnatis was 45 under a heat lamp, and weighed. The cell-associated radiomeasured in the direction of the conversion of pyruvate into
activity was determined in a liquid scintillation counter
lactate coupled to the oxidation of NADH as previously
(Wallac 1410; Pharmacia, Piscataway, N.J.) using EcoLite
described in the Worthington enzyme n~anual(Worthington
scintillation cocktail (ICN). Uptake data were expressed as
Biochemical Gorp., Lakewood, N.J.1. crude cell extracts
micromoles of D-alanine per milligram (dry cell weight).
were added to
m1 of prewarmed mixtures containing 50 50
Since radiolabeled DCS is not commercially available, an
mM Tris-HC1 (pH 8.0),
mM
pymvate (Sigma),
uptake assay was developed based on the colorimetric
and 0'2 mM NADH (Roche)' The change in absorbance at
determination of this compound (Jones, 1956). Cells expo340 nm was measured after 1 h of incubation at 37C. All
(OD6O0 of -'")
were
"entially growing in
samples were measured in triplicate, Specific activities (in
harvested
at
4C
washed
twice
with
water,
micromoles of consumed substrate minute-l milligram-l)
were calculated as described in the enzyme manual men- ss and concentrated 40 times. Samples were prewarmed at 37C
tioned above by subtracting the background change in
for 10 min, and DCS was added to a final concentration of
were placed in a 37C water
absorbance (obtained from boiled inactivated extracts pro250 MIm1 (-2.5 mM).
cessed in identical manner) from the change in absorbance
bath. Aliquots were taken at various times and immediately
placed on ice. After 20 min of incubation, clumping of
obtained with the active cell extracts.
60 TAM23 cells was evident and uptake determinations became
Example 2
unreliable. Each time a point sample was washed twice with
Generation of M. tubevculosis alrA Mutants
water, resuspended, and sonicated. Protein concentration
was determined using the Bio-Rad DC assay, followed by
Example 3
protein removal through serial passages of both YM-10 and
Drug Susceptibility Assays
65 YM-3 Centricon concentrators (Millipore Corp.). The conMICs were determined by a microplate twofold dilution
centration of DCS was determined by measuring the OD620
after adding a specific color-developing reagent as previmethod, as described by Takiff et al., 1996, with modifica37C3
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ously described (Jones, 1956). A standard curve was generRecombinant BCG as a candidate oral vaccine. Res. Microbiol. 141, 931-939.
ated by diluting a DCS standard in a cell extract that was
prepared from cells not exposed to DCS. Uptake data were
Belanger, A. E., and J. M. Inamine. 2000. Genetics of cell
wall biosynthesis, p. 191-202. In G. F. Hatfull and W. R.
expressed as micromoles of DCS per milligram of protein.
Since D-alanine and DCS uptake assays do not measure the s Jacobs, Jr. (ed.), Molecular genetics of mycobacteria. ASM
Press, Washington, D.C.
same parameters, reported values for each assay cannot be
Belanger, A. E., J. C. Porter, and G. F. Hatfull. 2000.
directly compared.
Genetic analysis of peptidoglycan biosynthesis in mycobacExample 5
teria: characterization of a ddlA mutant of Mycobactevium
lo smegmatis. J. Bacteriol. 182:6854-6856.
Increased Susceptibility to Phagocytic Cells
Bermudez, L. E. & Yound, L. S. (1988). Tumor necrosis
factor, alone or combination with IL-2, but not IFN-gamma,
Intracellular killing assays were carried out as described
previously with the following modifications (Bermudez and
is
with macrophage
of
lmmunol l4O9 3006-3013'
Young, 1988). Approximately 5x10' monocytes were
Berthet, F. X., Lagranderie, M., Gounon, P., C., L. W.,
seeded on each well of a 24-well tissue culture plate 1s
Ensergueix, D., Chavarot, P., Thouron, F., Maranghi, E.,
(Sigma). Plates were incubated for 2 h at 37 C in 5% CO,.
Pelicic, V., Portnoi, D., Marchal, G. & Giequel, B. (1998).
Supernatant fluids with nonadherent cells were removed and
Attenuation of virulence by disruption of the Mycobactethe wells were washed twice with 1.0 ml of prewarmed
tubevculosis erp gene' Science 2822 759-762'
HBSS. The adherent monocytes were maintained in culture
B1attner,F. R., V.
G. P1unkett II1, H. J.
and
for 7 days with 1.5 ml of RPMI 1640 (Gibco) supplemented 20
with mM L-glutamine (Sigma) and
heat-inactivated
D. L. Daniels. 1993. Analysis of the Eschevichia coli
genome. IV. DNA sequence of the region from 89.2 to 92.8
fetal bovine serum (Sigma), Culture media was replaced
every 48 hours. Each well was inoculated with approximately 5.0x106 CFU of bacteria. After 2 h, macrophage
monolayers were washed three times with HBSS to remove
extracellular microorganisms. Some wells were lysed immediately with 0.5 ml of sterile water for 10 min and 0.025%
SDS (Sigma) in HBSS for additional 10
SDS was
subsequently inactivated with 0.1% bovine albumin
(Sigma). The lysate was serially diluted and plated onto
Middlebrook 7H9 based agar (BBL) supplemented with
0.5% fraction V albumin (EM Science), 0.01 M dextrose
(Sigma), 0.015 M sodium chloride (Sigma), 0.15% glycerol
(Sigma) and 1.5% Bacto agar (Difco). The same procedure
was done on two other sets of wells at 24, 48 and 72 hours.
I l ~ r e wells
e
were carried out Per experimental group, in each
of three independent experiments. It is to be noted that a
preliminary experiment using 20 ~ g l mof
l amikacin during
the invasion step to kill extracellular bacteria yielded similar
results, demonstrating the effectiveness of the washing procedure.
While the invention has been disclosed in this patent
application by reference to the details of preferred embodiments of the invention, it is to be understood that the
disclosure is intended in an illustrative rather than in a
limiting sense, as it is contemplated that modifications will
readily occur to those skilled in the art, within the spirit of
the invention and the scope of the appended claims.
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What is claimed and desired to be secured by Letters
6. The recombinant mycobacteria of claim 1,wherein said
Patent is as follows:
recombinant mycobacteria further comprises one or more
1.A recombinant rnycobacteviurn comprising an inactiadditional mutations, whereby said recombinant mycobacvated alrAgene, wherein said rnycobacteviurn is independent
teria is rendered dependent on D-alanine for growth.
s 7. The recombinant mycobacteria of claim 1,wherein said
of D-alanine for growth.
2. The recombinant rnycobacteviurn of claim 1, wherein
recombinant mycobacteria displays increased susceptibility
to bactericidal action of phagocytic cells.
said rnycobacteviurn is selected from the group consisting of
Mycobacteviurn srnegrnatis, and subspecies thereof.
8. The recombinant mycobacteria of claim 1,wherein said
3. The recombinant mycobacteria of claim 1,wherein said
recombinant mycobacteria further comprises a single
recombinant mycobacteria further comprises one or more 10 D-alanine ligase gene under the control of an inducible
promoter, said promoter controlling the expression of
additional mutation encoding peptide or non-peptide antigens from a pathogenic mycobacteria.
D-alanyl-D-alanine.
4. The recombinant mycobacteria of claim 1,wherein said
9. The recombinant rnycobacteviurn of claim 2, wherein
recombinant mycobacteria displays increased susceptibility
said rnycobacteviurn is a strain designated TAM20.
to an antimycobacterial agent.
IS
10. The recombinant rnycobacteviurn of claim 2, wherein
5. The recombinant mycobacteria of claim 4, wherein said
said rnycobacteviurn is a strain designated TAM23.
antimycobacterial agent is selected from the group consist* * * * *
ing of D-cycloserine and other D-alanine analogs.

